Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?
Glioblastoma remains the most malignant and intrinsically resistant brain tumour in adults. Despite intensive research over the past few decades, through which numerous potentially druggable targets have been identified, virtually all clinical trials of the past 20 years have failed to improve the o...
Main Authors: | Dena Panovska, Frederik De Smet |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/15/8637 |
Similar Items
-
Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize
by: Michal Kýr, et al.
Published: (2020-03-01) -
The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology
by: Margaret Morash, et al.
Published: (2018-09-01) -
“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
by: Pan Pantziarka, et al.
Published: (2018-06-01) -
Editorial: Oral Oncology: From Precise Surgery to Precision Medicine and Surgery
by: Zuzana Saidak, et al.
Published: (2022-04-01) -
Heterogeneity in precision oncology
by: Bartłomiej Tomasik, et al.
Published: (2024-01-01)